Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.04 Million USD | 4.7% |
| 2022 | 16.84 Million USD | 7.33% |
| 2021 | 15.69 Million USD | 60.23% |
| 2020 | 9.79 Million USD | 17.72% |
| 2019 | 8.32 Million USD | 61.25% |
| 2018 | 5.16 Million USD | 4.36% |
| 2017 | 4.94 Million USD | 6.43% |
| 2016 | 4.64 Million USD | 50.31% |
| 2015 | 3.09 Million USD | 66.47% |
| 2014 | 1.85 Million USD | 121.82% |
| 2013 | 837.21 Thousand USD | 14.54% |
| 2012 | 730.91 Thousand USD | -12.19% |
| 2011 | 832.35 Thousand USD | 18.98% |
| 2010 | 699.57 Thousand USD | -2.02% |
| 2009 | 713.97 Thousand USD | 31.51% |
| 2008 | 542.92 Thousand USD | 23.64% |
| 2007 | 439.1 Thousand USD | 25.22% |
| 2006 | 350.67 Thousand USD | -29.91% |
| 2005 | 500.31 Thousand USD | -24.74% |
| 2004 | 664.77 Thousand USD | 152.29% |
| 2003 | 263.49 Thousand USD | 9.54% |
| 2002 | 240.53 Thousand USD | -13.82% |
| 2001 | 279.11 Thousand USD | -51.48% |
| 2000 | 575.2 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.82 Million USD | 7.88% |
| 2024 Q1 | 4.47 Million USD | -11.86% |
| 2023 FY | 17.63 Million USD | 4.7% |
| 2023 Q1 | 5.14 Million USD | 0.11% |
| 2023 Q2 | 4.73 Million USD | -8.14% |
| 2023 Q4 | 5.07 Million USD | -2.81% |
| 2023 Q3 | 5.22 Million USD | 10.44% |
| 2022 Q1 | 3.11 Million USD | -5.32% |
| 2022 FY | 16.84 Million USD | 7.33% |
| 2022 Q4 | 5.14 Million USD | 10.2% |
| 2022 Q3 | 4.66 Million USD | 18.94% |
| 2022 Q2 | 3.92 Million USD | 26.06% |
| 2021 Q3 | 4.24 Million USD | 11.33% |
| 2021 Q2 | 3.8 Million USD | -12.66% |
| 2021 FY | 15.69 Million USD | 60.23% |
| 2021 Q1 | 4.36 Million USD | 55.1% |
| 2021 Q4 | 3.28 Million USD | -22.46% |
| 2020 Q2 | 2.39 Million USD | -18.5% |
| 2020 FY | 9.79 Million USD | 17.72% |
| 2020 Q3 | 1.64 Million USD | -31.3% |
| 2020 Q4 | 2.81 Million USD | 70.72% |
| 2020 Q1 | 2.94 Million USD | 8.99% |
| 2019 Q1 | 2.1 Million USD | 33.33% |
| 2019 Q3 | 1.88 Million USD | 16.07% |
| 2019 Q4 | 2.69 Million USD | 42.9% |
| 2019 FY | 8.32 Million USD | 61.25% |
| 2019 Q2 | 1.62 Million USD | -22.82% |
| 2018 Q1 | 988.77 Thousand USD | -35.57% |
| 2018 Q3 | 1 Million USD | -37.04% |
| 2018 Q4 | 1.58 Million USD | 57.92% |
| 2018 FY | 5.16 Million USD | 4.36% |
| 2018 Q2 | 1.59 Million USD | 60.82% |
| 2017 Q2 | 1.27 Million USD | -0.97% |
| 2017 Q1 | 1.28 Million USD | 4.49% |
| 2017 Q4 | 1.53 Million USD | 78.79% |
| 2017 FY | 4.94 Million USD | 6.43% |
| 2017 Q3 | 858.38 Thousand USD | -32.67% |
| 2016 Q4 | 1.23 Million USD | 17.56% |
| 2016 Q1 | 1 Million USD | -5.03% |
| 2016 FY | 4.64 Million USD | 50.31% |
| 2016 Q2 | 1.39 Million USD | 38.95% |
| 2016 Q3 | 1.04 Million USD | -24.91% |
| 2015 Q2 | 675.29 Thousand USD | 26.47% |
| 2015 Q1 | 533.96 Thousand USD | -14.5% |
| 2015 Q4 | 1.05 Million USD | 28.25% |
| 2015 FY | 3.09 Million USD | 66.47% |
| 2015 Q3 | 824.62 Thousand USD | 22.11% |
| 2014 FY | 1.85 Million USD | 121.82% |
| 2014 Q1 | 281.68 Thousand USD | 33.71% |
| 2014 Q4 | 624.53 Thousand USD | 15.91% |
| 2014 Q3 | 538.81 Thousand USD | 48.21% |
| 2014 Q2 | 363.55 Thousand USD | 29.07% |
| 2013 Q3 | 241.21 Thousand USD | 24.22% |
| 2013 Q4 | 210.66 Thousand USD | -12.66% |
| 2013 Q2 | 194.17 Thousand USD | 1.58% |
| 2013 Q1 | 191.15 Thousand USD | 34.42% |
| 2013 FY | 837.21 Thousand USD | 14.54% |
| 2012 Q3 | 158.96 Thousand USD | -11.06% |
| 2012 Q4 | 142.2 Thousand USD | -10.54% |
| 2012 Q2 | 178.72 Thousand USD | -28.8% |
| 2012 Q1 | 251.01 Thousand USD | -11.75% |
| 2012 FY | 730.91 Thousand USD | -12.19% |
| 2011 FY | 832.35 Thousand USD | 18.98% |
| 2011 Q1 | 212.1 Thousand USD | 28.57% |
| 2011 Q2 | 151.04 Thousand USD | -28.79% |
| 2011 Q3 | 184.78 Thousand USD | 22.33% |
| 2011 Q4 | 284.41 Thousand USD | 53.92% |
| 2010 Q3 | 177.49 Thousand USD | 57.25% |
| 2010 Q1 | 244.24 Thousand USD | -15.51% |
| 2010 FY | 699.57 Thousand USD | -2.02% |
| 2010 Q2 | 112.87 Thousand USD | -53.79% |
| 2010 Q4 | 164.97 Thousand USD | -7.06% |
| 2009 Q3 | 146.16 Thousand USD | 21.79% |
| 2009 FY | 713.97 Thousand USD | 31.51% |
| 2009 Q1 | 158.75 Thousand USD | 13.96% |
| 2009 Q2 | 120 Thousand USD | -24.41% |
| 2009 Q4 | 289.06 Thousand USD | 97.77% |
| 2008 Q1 | 134.53 Thousand USD | 55.92% |
| 2008 Q4 | 139.3 Thousand USD | -5.43% |
| 2008 Q3 | 147.29 Thousand USD | 26.99% |
| 2008 Q2 | 115.99 Thousand USD | -13.78% |
| 2008 FY | 542.92 Thousand USD | 23.64% |
| 2007 Q3 | 116.99 Thousand USD | 37.81% |
| 2007 FY | 439.1 Thousand USD | 25.22% |
| 2007 Q4 | 86.28 Thousand USD | -26.25% |
| 2007 Q2 | 84.89 Thousand USD | -43.75% |
| 2007 Q1 | 150.93 Thousand USD | 377.74% |
| 2006 Q2 | 102.6 Thousand USD | 3.99% |
| 2006 FY | 350.67 Thousand USD | -29.91% |
| 2006 Q4 | 31.59 Thousand USD | -73.18% |
| 2006 Q3 | 117.81 Thousand USD | 14.82% |
| 2006 Q1 | 98.66 Thousand USD | -69.1% |
| 2005 FY | 500.31 Thousand USD | -24.74% |
| 2005 Q1 | 105.41 Thousand USD | 326.33% |
| 2005 Q2 | 104.61 Thousand USD | -0.76% |
| 2005 Q3 | 177.35 Thousand USD | 69.54% |
| 2005 Q4 | 319.31 Thousand USD | 80.04% |
| 2004 Q4 | 24.72 Thousand USD | -74.67% |
| 2004 FY | 664.77 Thousand USD | 152.29% |
| 2004 Q3 | 97.6 Thousand USD | -76.0% |
| 2004 Q2 | 406.74 Thousand USD | 259.81% |
| 2004 Q1 | 113.04 Thousand USD | -7.34% |
| 2003 Q1 | 49.22 Thousand USD | -31.83% |
| 2003 FY | 263.49 Thousand USD | 9.54% |
| 2003 Q4 | 122 Thousand USD | 168.09% |
| 2003 Q3 | 45.5 Thousand USD | -2.68% |
| 2003 Q2 | 46.76 Thousand USD | -5.01% |
| 2002 Q4 | 72.21 Thousand USD | 49.97% |
| 2002 Q2 | 56.75 Thousand USD | -10.5% |
| 2002 Q1 | 63.41 Thousand USD | -3.23% |
| 2002 Q3 | 48.15 Thousand USD | -15.16% |
| 2002 FY | 240.53 Thousand USD | -13.82% |
| 2001 Q2 | 71.44 Thousand USD | -22.29% |
| 2001 Q1 | 91.94 Thousand USD | -39.19% |
| 2001 FY | 279.11 Thousand USD | -51.48% |
| 2001 Q4 | 65.53 Thousand USD | -12.49% |
| 2001 Q3 | 74.89 Thousand USD | 4.82% |
| 2000 Q3 | 127.81 Thousand USD | 0.0% |
| 2000 FY | 575.2 Thousand USD | 0.0% |
| 2000 Q4 | 151.2 Thousand USD | 18.3% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -154.967% |
| Alpha Teknova, Inc. | 45.85 Million USD | 54.116% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 89.263% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 53.088% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 86.783% |
| Cosmos Health Inc. | 26.18 Million USD | 19.628% |
| Journey Medical Corporation | 54.59 Million USD | 61.457% |
| Embecta Corp. | 528.4 Million USD | 96.018% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 92.261% |
| Dynavax Technologies Corporation | 219.14 Million USD | 90.398% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 96.434% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 93.553% |
| PainReform Ltd. | 9.58 Million USD | -119.554% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -60.327% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -60.327% |
| SCYNEXIS, Inc. | 51.84 Million USD | 59.416% |
| Safety Shot Inc | 12.1 Million USD | -73.762% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -585.592% |
| Procaps Group, S.A. | 199.47 Million USD | 89.451% |
| Theratechnologies Inc. | 72.75 Million USD | 71.079% |
| Harrow Health, Inc. | 89.97 Million USD | 76.613% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -122.762% |
| Biofrontera Inc. | 39.95 Million USD | 47.341% |
| DURECT Corporation | 43.71 Million USD | 51.865% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 96.022% |
| Cronos Group Inc. | 96.7 Million USD | 78.242% |
| OptiNose, Inc. | 85.1 Million USD | 75.274% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 90.935% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 46.257% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 320.083% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 93.302% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -116.241% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 51.111% |
| Radius Health, Inc. | 265.92 Million USD | 92.087% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -52.017% |
| ProPhase Labs, Inc. | 37.85 Million USD | 44.41% |
| Phibro Animal Health Corporation | 260.29 Million USD | 91.916% |
| Procaps Group S.A. | 187.24 Million USD | 88.762% |
| Alvotech | 285.43 Million USD | 92.628% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -114.169% |
| Viatris Inc. | 5.96 Billion USD | 99.647% |
| Rockwell Medical, Inc. | 15.37 Million USD | -36.868% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 64.836% |
| SIGA Technologies, Inc. | 22.04 Million USD | 4.541% |
| Tilray Brands, Inc. | 251.35 Million USD | 91.629% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 57.09% |
| Shineco, Inc. | 17.94 Million USD | -17.239% |
| PetIQ, Inc. | 192.72 Million USD | 89.082% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -427.22% |
| Incannex Healthcare Limited | 30.05 Million USD | 29.983% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.682% |
| Alimera Sciences, Inc. | 62.64 Million USD | 66.408% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -2659.648% |
| Assertio Holdings, Inc. | 368.58 Million USD | 94.291% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -257.52% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -18.157% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 0.599% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 87.245% |
| Hempacco Co., Inc. | 7.59 Million USD | -176.999% |
| Talphera, Inc. | 11.99 Million USD | -75.439% |
| Alvotech | 285.43 Million USD | 92.628% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 85.046% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 93.899% |
| Currenc Group, Inc. | 24 Million USD | 12.332% |
| Kamada Ltd. | 45.42 Million USD | 53.678% |
| Indivior PLC | 911 Million USD | 97.69% |
| Evoke Pharma, Inc. | 12.4 Million USD | -69.562% |
| Flora Growth Corp. | 10.57 Million USD | -98.904% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 0.0% |
| Evolus, Inc. | 189.75 Million USD | 88.911% |
| HUTCHMED (China) Limited | 436.23 Million USD | 95.176% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 86.348% |
| Akanda Corp. | 3.48 Million USD | -504.049% |